ACRIVON THERAPEUTICS INC (ACRV) Fundamental Analysis & Valuation

NASDAQ:ACRV • US0048901096

Current stock price

1.6 USD
-0.06 (-3.61%)
Last:

This ACRV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ACRV Profitability Analysis

1.1 Basic Checks

  • In the past year ACRV has reported negative net income.
  • ACRV had a negative operating cash flow in the past year.
  • ACRV had negative earnings in each of the past 5 years.
  • ACRV had a negative operating cash flow in each of the past 5 years.
ACRV Yearly Net Income VS EBIT VS OCF VS FCFACRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • With a Return On Assets value of -56.26%, ACRV perfoms like the industry average, outperforming 44.12% of the companies in the same industry.
  • ACRV has a Return On Equity of -63.57%. This is comparable to the rest of the industry: ACRV outperforms 56.84% of its industry peers.
Industry RankSector Rank
ROA -56.26%
ROE -63.57%
ROIC N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ACRV Yearly ROA, ROE, ROICACRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • ACRV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRV Yearly Profit, Operating, Gross MarginsACRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ACRV Health Analysis

2.1 Basic Checks

  • ACRV has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACRV Yearly Shares OutstandingACRV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
ACRV Yearly Total Debt VS Total AssetsACRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -1.65, we must say that ACRV is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -1.65, ACRV perfoms like the industry average, outperforming 52.60% of the companies in the same industry.
  • ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.65
ROIC/WACCN/A
WACCN/A
ACRV Yearly LT Debt VS Equity VS FCFACRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 8.75 indicates that ACRV has no problem at all paying its short term obligations.
  • ACRV's Current ratio of 8.75 is fine compared to the rest of the industry. ACRV outperforms 76.69% of its industry peers.
  • A Quick Ratio of 8.75 indicates that ACRV has no problem at all paying its short term obligations.
  • The Quick ratio of ACRV (8.75) is better than 76.69% of its industry peers.
Industry RankSector Rank
Current Ratio 8.75
Quick Ratio 8.75
ACRV Yearly Current Assets VS Current LiabilitesACRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ACRV Growth Analysis

3.1 Past

  • ACRV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.11%, which is quite impressive.
EPS 1Y (TTM)21.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 6.28% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.05%
EPS Next 2Y9.78%
EPS Next 3Y7.3%
EPS Next 5Y6.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACRV Yearly Revenue VS EstimatesACRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
ACRV Yearly EPS VS EstimatesACRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. ACRV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACRV. In the last year negative earnings were reported.
  • Also next year ACRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRV Price Earnings VS Forward Price EarningsACRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRV Per share dataACRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.78%
EPS Next 3Y7.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACRV Dividend Analysis

5.1 Amount

  • ACRV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACRV Fundamentals: All Metrics, Ratios and Statistics

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (3/23/2026, 1:22:41 PM)

1.6

-0.06 (-3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners59.01%
Inst Owner Change5.13%
Ins Owners8.2%
Ins Owner Change-0.45%
Market Cap50.50M
Revenue(TTM)N/A
Net Income(TTM)-81.75M
Analysts82.67
Price Target11.73 (633.13%)
Short Float %8.52%
Short Ratio1.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.96%
Min EPS beat(2)8.02%
Max EPS beat(2)21.9%
EPS beat(4)4
Avg EPS beat(4)16%
Min EPS beat(4)8.02%
Max EPS beat(4)22.15%
EPS beat(8)6
Avg EPS beat(8)9.81%
EPS beat(12)10
Avg EPS beat(12)10.46%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.14%
EPS NY rev (1m)0%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS4.07
TBVpS4.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.26%
ROE -63.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.42%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.75
Quick Ratio 8.75
Altman-Z -1.65
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)372.74%
Cap/Depr(5y)383.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
EPS Next Y16.05%
EPS Next 2Y9.78%
EPS Next 3Y7.3%
EPS Next 5Y6.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.96%
OCF growth 3YN/A
OCF growth 5YN/A

ACRIVON THERAPEUTICS INC / ACRV Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ACRIVON THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ACRV.


What is the valuation status of ACRIVON THERAPEUTICS INC (ACRV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACRIVON THERAPEUTICS INC (ACRV). This can be considered as Overvalued.


Can you provide the profitability details for ACRIVON THERAPEUTICS INC?

ACRIVON THERAPEUTICS INC (ACRV) has a profitability rating of 1 / 10.


How financially healthy is ACRIVON THERAPEUTICS INC?

The financial health rating of ACRIVON THERAPEUTICS INC (ACRV) is 7 / 10.